Latest Observability News

Lachlan Star has delivered further high-grade gold hits from its maiden diamond drilling at New Waverley, confirming a shallow, continuous quartz vein system with strike potential beyond 800 metres. A substantial reverse circulation drilling campaign is poised to expand the discovery.

ReadyTech Holdings has dismissed an unsolicited acquisition proposal valuing the company at $2.00 per share, calling it undervalued and unworkable. The offer includes a parallel off-market bid at $1.75 per share with a 50.1% minimum acceptance condition.

FortifAI has appointed Kelly Herrell, a seasoned Silicon Valley CEO with a track record of scaling infrastructure tech companies to IPO and acquisition, as its new CEO. Herrell’s leadership aims to accelerate commercialisation of FortifAI’s AI Data Plane technology through its Nol8 subsidiary.

Final assays from drillhole 26LHDD073 at the Southern Porphyry target within the Llahuin Project Joint Venture validate a broad copper-gold-molybdenum mineralised system. Integration of geological and geophysical data aims to pinpoint the higher-grade core ahead of Phase II drilling.

Chimeric Therapeutics reports encouraging Phase 1/2 data for its CHM CDH17 CAR-T therapy in advanced gastrointestinal cancers, with 82% of evaluable patients achieving stable disease and durable responses lasting over a year.

Trek Metals has marked a breakthrough year with a high-grade manganese discovery at its Christmas Creek Project in Western Australia, supported by strong assay results and expanded exploration tenure. The company bolstered its balance sheet with $19.5 million raised to fund drilling and further exploration.

FMR Resources has received final assays from drillhole 26LHDD073 at its Southern Porphyry target, confirming extensive copper-gold-molybdenum mineralisation and supporting the interpretation of a large porphyry system. Ongoing integration of geological and geophysical data aims to refine targets ahead of Phase II drilling.

Amplia Therapeutics reported encouraging mature data from its ACCENT pancreatic cancer trial showing improved survival and response rates with narmafotinib. The company raised $27.5 million to fund development and manufacturing scale-up, while discontinuing a parallel trial due to chemotherapy toxicity.

Haranga Resources has wrapped up its Phase 3 Reverse Circulation drilling at Senegal’s Ibel South, revealing pervasive hydrothermal alteration and pyrite mineralisation consistent with a Birimian-style gold system. Assay results expected by end June will determine the next exploration steps.

OncoSil Medical has secured a pivotal ethics committee approval in Italy, reclassifying its OSPRItaly registry and enabling a streamlined procurement process that could double the number of authorised hospitals using its OncoSil™ device by mid-2027.

Nex Metals has verified a 5-kilometre stretch of gold-bearing quartz veins at its North Henai project in Egypt, setting the stage for systematic assays and shallow diamond drilling within months.

Osmond Resources has unveiled new channel sample assays from Spain’s Orión project, revealing outstanding heavy mineral grades that strengthen the case for its maiden Mineral Resource Estimate. Phase 2 drilling is poised to start pending final approvals, while a Scoping Study advances towards completion in late 2026.